NASDAQ:AMRS - Amyris Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $18.23
  • Forecasted Upside: 15.13 %
  • Number of Analysts: 6
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
▼ -0.25 (-1.55%)
1 month | 3 months | 12 months
Get New Amyris Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for AMRS and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for AMRS

Average Price Target: $18.23
▲ +15.13% Upside Potential
This price target is based on 6 analysts offering 12 month price targets for Amyris in the last 3 months. The average price target is $18.23, with a high forecast of $35.00 and a low forecast of $3.35. The average price target represents a 15.13% upside from the last price of $15.83.


The current consensus among 6 investment analysts is to buy stock in Amyris. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 2 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
6/1/2021HSBCInitiated CoverageBuy$20.00Medium
3/4/2021Roth CapitalBoost Price TargetBuy$20.00 ➝ $33.00N/A
3/3/2021HC WainwrightBoost Price TargetBuy$11.00 ➝ $35.00High
2/26/2021Roth CapitalInitiated CoveragePositive ➝ Buy$20.00High
1/6/2021CowenUpgradeMarket Perform ➝ Outperform$9.00N/A
12/16/2020HC WainwrightReiterated RatingBuyHigh
11/25/2020Jefferies Financial GroupInitiated CoverageBuy$3.35High
11/25/2020CowenInitiated CoverageMarket Perform$5.00High
9/11/2020OppenheimerReiterated RatingBuy$9.00Low
7/27/2020OppenheimerReiterated RatingBuy$9.00High
6/5/2020OppenheimerInitiated CoverageBuy$9.00High
2/3/2020OppenheimerReiterated RatingBuyMedium
12/11/2019OppenheimerInitiated CoverageOutperform$8.00Low
10/11/2019HC WainwrightReiterated RatingBuy$11.00High
2/5/2019HC WainwrightSet Price TargetBuy$11.00High
12/31/2018HC WainwrightReiterated RatingBuy$11.00Medium
12/4/2018HC WainwrightSet Price TargetBuy$11.00High
11/28/2018HC WainwrightSet Price TargetBuy$11.00Medium
11/14/2018HC WainwrightSet Price TargetBuy$11.00High
11/14/2018B. RileyLower Price TargetBuy ➝ Buy$10.00 ➝ $8.00High
10/4/2018HC WainwrightSet Price TargetBuy$15.00Medium
10/3/2018B. RileySet Price TargetBuy$10.00High
9/28/2018HC WainwrightSet Price TargetBuy$15.00Medium
9/17/2018B. RileySet Price TargetBuy$10.00Low
9/17/2018HC WainwrightSet Price TargetBuy$15.00Low
8/30/2018HC WainwrightSet Price TargetBuy$15.00High
8/7/2018HC WainwrightReiterated RatingBuy$15.00High
6/26/2018HC WainwrightReiterated RatingBuy$15.00High
5/29/2018B. RileySet Price TargetBuy$10.00Low
5/25/2018HC WainwrightSet Price TargetBuy$15.00Medium
5/20/2018B. RileySet Price TargetBuy$10.00Low
5/15/2018HC WainwrightSet Price TargetBuy$15.00Low
4/2/2018HC WainwrightReiterated RatingBuy$15.00Low
3/20/2018B. RileySet Price TargetBuy ➝ Buy$8.00 ➝ $10.00Low
1/25/2018B. RileyInitiated CoverageBuy ➝ Buy$8.00Low
1/18/2018HC WainwrightReiterated RatingBuy$15.00Medium
11/29/2017HC WainwrightSet Price TargetBuy$15.00High
11/29/2017CowenReiterated RatingHold$4.00High
11/15/2017HC WainwrightReiterated RatingBuy$15.00N/A
9/26/2017HC WainwrightReiterated RatingBuy$15.00Low
8/17/2017CowenSet Price TargetHold$4.00High
8/11/2017HC WainwrightSet Price TargetBuy$15.00High
6/7/2017HC WainwrightSet Price TargetBuy$15.00Low
5/23/2017HC WainwrightReiterated RatingBuy$60.00Medium
1/11/2017Rodman & RenshawReiterated RatingBuy$60.00N/A
1/10/2017HC WainwrightSet Price TargetBuy$60.00N/A
9/28/2016Singular ResearchReiterated RatingBuy$42.00N/A
(Data available from 6/20/2016 forward)
Amyris logo
Amyris, Inc., a synthetic biotechnology company, operates in the clean health and beauty markets through its consumer brands and as a supplier of sustainable and natural ingredients in Europe, the United States, Asia, Brazil, and internationally. It manufactures and sells products for the health and wellness, clean beauty, and flavor and fragrance markets. The company operates under the Amyris, Biofene, Biossance, Pipette, Purecane, and No Compromise trademarks. Amyris, Inc. has a collaboration agreement with the Infectious Disease Research Institute to advance a novel ribonucleic acid vaccine platform, including accelerating the development of a COVID-19 vaccine. The company was formerly known as Amyris Biotechnologies, Inc. and changed its name to Amyris, Inc. in June 2010. Amyris, Inc. was incorporated in 2003 and is headquartered in Emeryville, California.
Read More

Today's Range

Now: $15.83
Low: $15.59
High: $16.29

50 Day Range

MA: $14.34
Low: $10.82
High: $16.12

52 Week Range

Now: $15.83
Low: $1.88
High: $23.42


6,919,115 shs

Average Volume

4,510,170 shs

Market Capitalization

$4.68 billion

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Amyris?

The following Wall Street sell-side analysts have issued reports on Amyris in the last year: Cowen Inc, HC Wainwright, HSBC Holdings plc, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., Roth Capital, and Zacks Investment Research.
View the latest analyst ratings for AMRS.

What is the current price target for Amyris?

6 Wall Street analysts have set twelve-month price targets for Amyris in the last year. Their average twelve-month price target is $18.23, suggesting a possible upside of 15.1%. HC Wainwright has the highest price target set, predicting AMRS will reach $35.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $3.35 for Amyris in the next year.
View the latest price targets for AMRS.

What is the current consensus analyst rating for Amyris?

Amyris currently has 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe AMRS will outperform the market and that investors should add to their positions of Amyris.
View the latest ratings for AMRS.

What other companies compete with Amyris?

How do I contact Amyris' investor relations team?

Amyris' physical mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company's listed phone number is 510-450-0761 and its investor relations email address is [email protected] The official website for Amyris is